

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/080379 A1

(51) International Patent Classification⁷: **C07D 401/14**,
413/14, A61K 31/4439, A61P 25/00, 29/00, 1/00

WENSBO, David [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/US2005/005200

(74) Agents: BENT, Stephen, A. et al.; Foley & Lardner LLP, Washington Harbour, 3000 K Street, NW, Suite 500, Washington, DC 20007-5143 (US).

(22) International Filing Date: 17 February 2005 (17.02.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/545,289

18 February 2004 (18.02.2004) US

(71) Applicants (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE). **NPS PHARMACEUTICALS, INC.** [US/US]; 383 Colow Drive, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EDWARDS, Louise** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **ISAAC, Methvin** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **JOHANSSON, Martin** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE). **MALMBERG, Johan** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE). **MINDIS, Alexander** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE). **STAAR, Karin** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE). **SLASSI, Abdelmalik** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS**

(57) Abstract: The present invention relates to new compounds of formula (I), wherein P, Q, X¹, X², X³, X⁴, X⁷, X⁸, R¹, R², R³, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy, especially for the treatment of mGluR5 receptor mediated disorders, and for the treatment of neurological disorders, psychiatric disorders, gastrointestinal disorders and pain disorders.



WO 2005/080379 A1